Latest News
Lundbeck to present new Vyepti and bocunebart migraine data at EAN 2026
24 June 2026 - Biopharmaceutical company H. Lundbeck A/S (XCSE: HLUN A) reported on Wednesday that it will present new clinical data from its migraine portfolio at the European Academy of Neurology (EAN) Congress 2026 in Geneva, highlighting both app...
Natera Signatera gains PMDA approval in Japan for colorectal cancer testing
24 June 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) announced on Wednesday that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for use in colore...
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead RNA therapeutic candidate, miRisten, for Acute My...
Circio and Tcelltech partner on next-generation CAR-T cell therapy research
24 June 2026 - Circio Holding ASA (OSE:CRNA) a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, announced on Wednesday that it has formed a CAR-T cell therapy research collaboration with Tcelltech G...
Essange Reagents and Gentian Diagnostics agree collaboration on diagnostic assay development
24 June 2026 - Gentian Diagnostics (OSE:GENT), a Norway-based developer of in vitro diagnostic reagents, said on Wednesday that it is planning to enter into a collaboration agreement with Essange Reagents, a Netherlands-based developer of specialty i...